Efficacy and safety of erenumab in patients with episodic migraine in East Asia: Taiwan and Korea subpopulation analysis of the EMPOwER study

被引：0
|
作者：
Wang, S. [1 ]
Kim, Kun B. [2 ]
Lima, da Silva G. P. [3 ]
Pandhi, S. [4 ]
Wen, S. [5 ]
Mondal, S. [6 ]
Hours-Zesiger, P. [4 ]
机构：
[1] Taipei Vet Gen Hosp, Neurol Inst, Taipei, Taiwan
[2] Eulji Univ, Sch Med, Seoul, South Korea
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
[4] Novartis Pharma AG, Basel, Switzerland
[5] Novartis Pharmaceut, E Hanover, NJ USA
[6] Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, India
来源：
HEADACHE | 2021年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-188
引用
收藏
页码：124 / 124
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed
    Reuter, Uwe
    Goadsby, Peter J.
    Ferrari, Michel D.
    Da Silva Lima, Gabriel Paiva
    Mondal, Subhayan
    Kalim, Jawed
    Hasan, Fatima
    Wen, Shihua
    Arkuszewski, Michal
    Pandhi, Shaloo
    Stites, Tracy
    Lanteri-Minet, Michel
    NEUROLOGY, 2024, 102 (10)
  • [32] Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety
    Lattanzi, Simona
    Brigo, Francesco
    Trinka, Eugen
    Vernieri, Fabrizio
    Corradetti, Tommaso
    Dobran, Mauro
    Silvestrini, Mauro
    DRUGS, 2019, 79 (04) : 417 - 431
  • [33] Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis
    Tepper, Stewart J.
    Lipton, Richard B.
    Silberstein, Stephen D.
    Kudrow, David
    Ashina, Messoud
    Reuter, Uwe
    Dodick, David W.
    Wang, Andrea
    Cheng, Sunfa
    Klatt, Jan
    Mikol, Daniel D.
    HEADACHE, 2023, 63 (06): : 730 - 742
  • [34] Erenumab for Preventive Treatment of Migraine: A Systematic Review and Meta-Analysis of Efficacy and Safety
    Simona Lattanzi
    Francesco Brigo
    Eugen Trinka
    Fabrizio Vernieri
    Tommaso Corradetti
    Mauro Dobran
    Mauro Silvestrini
    Drugs, 2019, 79 : 417 - 431
  • [35] Efficacy and safety of erenumab in episodic migraine patients with 2-4 prior preventive treatment failures: Results from the Phase 3b LIBERTY study
    Reuter, Uwe
    Goadsby, Peter J.
    Lanteri-Minet, Michel
    Ferrari, Michel
    Wen, Shihua
    Klatt, Jan
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [36] Efficacy and Safety of Erenumab in Episodic Migraine Patients with 2-4 Prior Preventive Treatment Failures: Results from the Phase 3b LIBERTY Study
    Goadsby, P. J.
    Lanteri-Minet, M.
    Ferrari, M.
    Wen, S.
    Klatt, J.
    HEADACHE, 2018, 58 : 77 - 77
  • [37] Erenumab (AMG 334) in episodic migraine Interim analysis of an ongoing open-label study
    Ashina, Messoud
    Dodick, David
    Goadsby, Peter J.
    Reuter, Uwe
    Silberstein, Stephen
    Zhang, Feng
    Gage, Julia R.
    Cheng, Sunfa
    Mikol, Daniel D.
    Lenz, Robert A.
    NEUROLOGY, 2017, 89 (12) : 1237 - 1243
  • [38] EFFICACY AND SAFETY OF ERENUMAB IN EPISODIC MIGRAINE PATIENTS WITH 2-4 PRIOR PREVENTIVE TREATMENT FAILURES: RESULTS FROM THE PHASE 3B LIBERTY STUDY
    Reuter, U.
    Goadsby, P. J.
    Lanteri-Minet, M.
    Ferrari, M. D.
    Wen, S.
    Hours-Zesiger, P.
    Klatt, J.
    CEPHALALGIA, 2018, 38 : 60 - 60
  • [39] Safety and tolerability of erenumab in older migraine patients: A subgroup analysis of randomised trials
    Lampl, Christian
    Snellman, Josefin
    Ritter, Shannon
    Klatt, Jan
    NEUROLOGY, 2020, 94 (15)
  • [40] Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
    Wang, Shuu-Jiun
    Kim, Byung-Kun
    Wang, Hebo
    Zhou, Jiying
    Wan, Qi
    Yu, Tingmin
    Lian, Yajun
    Arkuszewski, Michal
    Ecochard, Laurent
    Snellman, Josefin
    Wen, Shihua
    Yin, Fangfang
    Li, Zheng
    Su, Wendy
    Yu, Shengyuan
    HEADACHE, 2025, 65 (01): : 143 - 152
12345